help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on January 25, 2005
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2004-0875
A more recent version of this article appeared on April 1, 2005
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
90/4/2117    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sakharova, A. A.
Right arrow Articles by Barkan, A. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sakharova, A. A.
Right arrow Articles by Barkan, A. L.

Submitted on May 11, 2004
Accepted on January 14, 2005

CLINICALLY "SILENT" SOMATOTROPINOMAS MAY BE BIOCHEMICALLY ACTIVE

Alla A. Sakharova, Eleni V. Dimaraki, William F. Chandler, and Ariel L. Barkan*

Department of Internal Medicine, Division of Endocrinology and Metabolism, University of Michigan Medical Center (A.A.S., E.V.D, A.L.B), Department of Neurosurgery, University of Michigan Medical Center (W.F.C.) and Department of Veterans Affairs Medical Center (A.L.B.), Ann Arbor, Michigan, 48109

* To whom correspondence should be addressed. E-mail: abarkan{at}umich.edu.

The diagnosis of acromegaly is suspected based on the typical clinical presentation and is subsequently confirmed biochemically by elevated growth hormone (GH) and insulin-like growth factor I (IGF-I) concentrations.

We report 3 female patients with pituitary tumors who presented without any signs or symptoms of acromegaly but with elevated IGF-I levels. Plasma GH was measured every 10 min for 24 h and oral glucose tolerance test (OGTT) was performed. All patients had abnormally elevated mean and trough plasma GH levels as well as post- glucose nadir GH concentrations. All patients had MRI scans revealing pituitary tumors and underwent transsphenoidal surgery. Histologically, they had GH- producing pituitary tumors. Plasma IGF-I levels returned to normal in 2 patients after surgery.

Some pituitary adenomas are true GH- secreting tumors despite not being accompanied by obvious clinical stigmata of acromegaly. Natural history of this disease is unknown due to small number of reported patients and inconsistent results of biochemical testing. Based on the results of this and previous reports, we propose that all patients with known pituitary tumors, especially younger women with normal or mildly elevated prolactin level be evaluated for GH excess.


Key words: acromegaly • GH • IGF-I • pituitary • adenoma




This article has been cited by other articles:


Home page
NEJMHome page
S. Melmed
Acromegaly
N. Engl. J. Med., December 14, 2006; 355(24): 2558 - 2573.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2005 by The Endocrine Society